Literature DB >> 2201926

Clinical relevance of measuring GABA concentrations in cerebrospinal fluid.

P J Schechter1, A Sjoerdsma.   

Abstract

Determination of GABA concentrations in human cerebrospinal fluid can be used to assess GABAergic activity in the central nervous system. As CSF free GABA concentrations may vary with age, sex, CSF fraction, and collection and storage conditions, careful attention to these factors are necessary to allow interpretation of results. Longitudinal studies to investigate the influence of pharmacological agents on CSF GABA have proven especially useful to define clinical biochemical activity and have been utilized to attribute the anti-epileptic action of vigabatrin, a selective inhibitor of GABA-transaminase, to its effects on brain GABA metabolism.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2201926     DOI： 10.1007/bf00969927

Source DB:  PubMed          Journal:  Neurochem Res        ISSN： 0364-3190            Impact factor:   3.996


  44 in total

1.  GABA levels in cerebrospinal fluid of patients with Huntington's chorea: a preliminary report.

Authors:  B S Glaeser; W H Vogel; D B Oleweiler; T A Hare
Journal:  Biochem Med       Date:  1975-04

2.  Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors.

Authors:  P J Schechter; Y Tranier; M J Jung; P Böhlen
Journal:  Eur J Pharmacol       Date:  1977-10-15       Impact factor: 4.432

3.  Identification of N-carboxyethyl gamma-aminobutyric acid in bovine brain and human cerebrospinal fluid.

Authors:  F Fussi; F Savoldi; M Curti
Journal:  Neurosci Lett       Date:  1987-06-26       Impact factor: 3.046

4.  gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice.

Authors:  M J Jung; B Lippert; B W Metcalf; P Böhlen; P J Schechter
Journal:  J Neurochem       Date:  1977-11       Impact factor: 5.372

5.  Automated assay of gamma-aminobutyric acid in human cerebrospinal fluid.

Authors:  P Böhlen; P J Schechter; W van Damme; G Coquillat; J C Dosch; J Koch-Weser
Journal:  Clin Chem       Date:  1978-02       Impact factor: 8.327

6.  Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases.

Authors:  H Kuroda; N Ogawa; Y Yamawaki; I Nukina; T Ofuji; M Yamamoto; S Otsuki
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-03       Impact factor: 10.154

7.  Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy.

Authors:  P J Schechter; N F Hanke; J Grove; N Huebert; A Sjoerdsma
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

8.  Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders.

Authors:  S J Enna; L Z Stern; G J Wastek; H I Yamamura
Journal:  Arch Neurol       Date:  1977-11

9.  Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa.

Authors:  B V Manyam
Journal:  Arch Neurol       Date:  1982-07

10.  Decreased CSF concentrations of homovanillic acid and gamma-aminobutyric acid in Alzheimer's disease. Age- or disease-related modifications?

Authors:  S R Bareggi; M Franceschi; L Bonini; L Zecca; S Smirne
Journal:  Arch Neurol       Date:  1982-11
View more
  4 in total

1.  Free-GABA levels in the cerebrospinal fluid of patients suffering from several neurological diseases Its potential use for the diagnosis of diseases which course with inflammation and tissular necrosis.

Authors:  A T Zepeda; F J Ortiz Nesme; J Méndez-Franco; E Otero-Siliceo; M Pérez de la Mora
Journal:  Amino Acids       Date:  1995-09       Impact factor: 3.520

Review 2.  Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.

Authors:  O A Petroff; D L Rothman
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

3.  Elevated plasma gamma-aminobutyric acid (GABA) levels in individuals with either Prader-Willi syndrome or Angelman syndrome.

Authors:  M H Ebert; D E Schmidt; T Thompson; M G Butler
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1997       Impact factor: 2.198

4.  Fluoxetine partly exerts its actions through GABA: a neurochemical evidence.

Authors:  M Zafer Gören; Esra Küçükibrahimoglu; Kemal Berkman; Berna Terzioglu
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.